The CBX3 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the CBX3 gene in the A2780 human epithelial ovarian cancer cell line. This polyclonal pool provides a heterogeneous loss-of-function model for studying the roles of heterochromatin protein 1 gamma (HP1??) without clonal selection bias. The use of a polyclonal format enables researchers to average out clonal variations and focus on the collective impact of CBX3 disruption across diverse genetic backgrounds.
The A2780 cell line was established from an ovarian carcinoma of an untreated patient and exhibits an epithelial morphology characteristic of high-grade serous ovarian cancer. Widely employed as a model for ovarian carcinoma biology, A2780 cells are particularly valued in drug resistance studies, including investigations into platinum-based chemotherapeutic agents such as cisplatin. Their well-characterized genomic landscape and reproducible in vitro growth make them a robust host for genetic perturbation and functional genomics.
CBX3 encodes HP1??, a core component of pericentric and telomeric heterochromatin that specifically recognizes histone H3 dimethylated or trimethylated at lysine 9 (H3K9me2/me3) through its chromodomain. This interaction is essential for chromatin compaction and transcriptional repression. HP1?? functions as a molecular scaffold, recruiting factors such as SUV39H1, SETDB1, and G9a to reinforce H3K9 methylation, and it also interacts with other HP1 family members (CBX1, CBX5), the lamin B receptor, and chromatin assembly factor 1 (CAF-1). Its activity is modulated by Aurora B kinase phosphorylation, which can displace HP1?? from chromatin during mitosis. Through these complexes, HP1?? mediates silencing of tumor suppressor genes like p16INK4a and E-cadherin, and it contributes to the repression of repetitive elements and maintenance of genome stability.
Disruption of CBX3 in A2780 cells abolishes HP1?? binding to H3K9me3, leading to heterochromatin decondensation and transcriptional de-repression of previously silenced loci. This epigenetic reprogramming can dysregulate cell cycle control, apoptosis, and DNA damage response pathways. In the context of ovarian cancer, loss of HP1?? may alter sensitivity to cisplatin, modulate metastatic potential, and reveal vulnerabilities associated with heterochromatin dysfunction. The polyclonal knockout population is therefore a powerful tool for dissecting how HP1??-mediated chromatin organization influences tumor cell behavior and therapeutic response.
This CBX3 knockout model supports a broad range of research applications, including the study of epigenetic regulatory mechanisms, heterochromatin maintenance, and drug resistance in ovarian cancer. Typical assays include chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K9me3 enrichment at target loci, western blotting to verify loss of CBX3 and changes in other HP1 proteins, RNA-seq for transcriptome-wide profiling of derepressed genes, and immunofluorescence microscopy to visualize heterochromatin foci disruption. Functional studies can employ cell proliferation assays, cisplatin sensitivity dose?Cresponse curves, and apoptosis detection by annexin V staining or caspase activation. By applying these approaches, researchers can connect CBX3-dependent chromatin states to phenotype. For further details or to customize this product for your experimental system, please contact Ascent Research.
